What are the appropriate methimazole dosing regimens and safety considerations for adults, children, elderly, and pregnant patients with Graves disease?

Methimazole Dosing and Considerations

Methimazole should be used as first-line antithyroid drug therapy in virtually all patients with Graves' disease, with initial dosing of 10-20 mg daily for adults (given once daily), 0.2-0.5 mg/kg/day for children, and the critical exception being first-trimester pregnancy when propylthiouracil must be used instead. 1

Adult Dosing

Initial Therapy

• Mild hyperthyroidism: 10-15 mg daily once daily 1, 2
• Moderate hyperthyroidism: 30-40 mg daily 2
• Severe hyperthyroidism: 60 mg daily 2

The FDA label recommends dividing doses every 8 hours 2, but once-daily dosing is equally effective and improves adherence (83% vs 53% with multiple daily PTU doses) 1. Recent practice patterns show 74.4% of Japanese clinicians initiate with 15 mg once daily 3.

Maintenance Therapy

After achieving euthyroidism (typically 4-8 weeks), titrate down to 5-10 mg daily 1. The maintenance dose before discontinuation is 2.5-5 mg/day in most patients 3. Avoid "block-and-replace" therapy (high-dose methimazole plus levothyroxine) as it increases adverse events without improving outcomes 1.

Pediatric Dosing

Use methimazole in virtually every child—propylthiouracil carries unacceptable hepatotoxicity risk in this population 1.

Initial Dosing

• Standard range: 0.2-0.5 mg/kg/day once daily 1
• FDA recommendation: 0.4 mg/kg/day divided every 8 hours 2
• Practical approach by age:
  • Infants: 1.25 mg/day
  • 1-5 years: 2.5-5 mg/day
  • 5-10 years: 5-10 mg/day
  • 10-18 years: 10-20 mg/day 1

Critical safety consideration: Doses >0.7 mg/kg/day significantly increase adverse events (42.9% vs 12.8% with lower doses), particularly neutropenia (21.4% vs 0% with <0.4 mg/kg/day), without improving time to euthyroidism 4. Do not exceed 0.7 mg/kg/day as initial therapy in children 5, 4.

Maintenance

Reduce to approximately 50% of initial dose once euthyroid 2. Continue for 24-36 months in children (longer than the 12-18 months used in adults) 6.

Pregnancy Dosing

This is the most critical exception to methimazole-first strategy:

First Trimester (Weeks 0-13)

Use propylthiouracil exclusively due to methimazole's association with aplasia cutis and choanal/esophageal atresia 1, 7. If a woman on methimazole becomes pregnant, switch to propylthiouracil immediately upon positive pregnancy test 1.

Second and Third Trimesters (Week 14 onward)

Switch from propylthiouracil to methimazole at the beginning of the second trimester due to PTU's rare but potentially fatal hepatotoxicity 1, 7. Use a conversion ratio of approximately 20-30:1 (e.g., 300 mg PTU ≈ 10-15 mg methimazole) 1.

Dosing Goals During Pregnancy

Use the lowest possible dose to maintain maternal free T4 at or slightly above the upper limit of the non-pregnant reference range (or total T4 at 1.5× upper normal limit), keeping TSH suppressed 1, 7. Monitor monthly and adjust accordingly 1. Avoid block-and-replace therapy—it increases fetal hypothyroidism risk 1.

Lactation

Methimazole is safe during breastfeeding at doses ≤10 mg/day, with no adverse effects on infant thyroid function or neurodevelopment 1, 6. In practice, 78.7% of lactating mothers receive ≤10 mg/day 3.

Elderly Considerations

Treat subclinical hyperthyroidism (TSH <0.1 mU/L) in all patients ≥65 years due to cardiovascular and bone risks 1. Use the same dosing principles as younger adults, but monitor more closely for cardiac complications 1.

Safety Monitoring

Baseline Testing

Before initiating therapy, obtain:

• Complete blood count with differential
• Liver function tests (bilirubin, transaminases, alkaline phosphatase in children) 1

Patient Education

At every visit, instruct patients to stop methimazole immediately and contact you if they develop:

• Fever or pharyngitis (agranulocytosis warning)
• Jaundice, dark urine, or acolic stools (hepatotoxicity)
• Pruritic rash
• Arthralgias, abdominal pain, nausea, or fatigue 1

Common Pitfalls

1. Agranulocytosis occurs in <1% but is potentially fatal. It typically appears early in treatment and may be dose-related 1. Lower maintenance doses (5-10 mg) may reduce risk 1.

2. Hepatotoxicity is rare with methimazole (unlike PTU's fulminant hepatic necrosis risk) 1.

3. Over-treatment causing fetal hypothyroidism in pregnancy—this is why you must use the lowest effective dose and monitor monthly 1.

4. Switching drugs mid-pregnancy requires careful dose conversion and thyroid function testing 2 weeks after the switch, then every 2-4 weeks 7.

Duration of Therapy

Standard course is 12-18 months for adults 1, 6 and 24-36 months for children 1, 6. However, recent evidence shows continuous therapy ≥60 months produces substantially higher sustained remission rates (<20% relapse vs ~50% with conventional courses) with minimal late adverse events 8. Consider extended therapy in patients with persistently elevated TSH-receptor antibodies at 12-18 months 6.